Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01621243
Recruitment Status : Terminated (The study was terminated after a pre-planned futility analyses showed an insufficient level of efficacy in the study population to warrant continuation.)
First Posted : June 18, 2012
Last Update Posted : August 29, 2018
Information provided by (Responsible Party):
Momenta Pharmaceuticals, Inc.